We would love to hear your thoughts about our site and services, please take our survey here.
Morning all invested
Great positivity from many based on facts & opinion posted
Below paragraph sums up recent RNS & underpinned by prevail -
As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike..
Add to the concoction-
Haywain - very informative posts
JFTH - Vlads interview posted
Ortex - noted positive outlook
& Prevail stood behind underpinning the pharma deals .
The Hemo Grog will eventually flow on a substantial stock re rate imo .
Evening all
Hold a small position here & have traded the crazy volatility in recent weeks for Rum cash , however looks a decent LT hold/buy with recent drilling RNS etc ,
so will keep my eyes watching with a bag of dry powder .
A Few numbers for anyone interested - 👍
( source - Ortex )
In the industrial gases sector, Helium One Global Ltd has recently outpaced its counterparts, with a notable increase of 290 +% over its peers in recent months
The stock's price performance over the past week has seen a 13.05% uptick, while its Year-To-Date price change stands at an impressive 750+%
. Additionally, Relative Strength Index (RSI) is registered at 59
Stock on loan / shorts
2.7million - down 300k - apprix 70k value
3 million - 1 month ago
Cost to borrow - 51
Dtc - 5.6
No flagged shorts to report
MCap - 80 million
Heavy volume in recent sessions
Vol 450 million - today & loaded with some hefty kippers
22-Feb-24 10:52:37 2.5846 4,650,721 Unknown* 2.40 2.45 120.20k O
Average vol 385 million
52 week high 10p
52 week low - 0.2p
Technical trading indicators pointing to strong buy - investing.com
Good luck all invested here in these volatile markets , however it does tend to bring out the good , the bad & the ugly .
Evening investors
Below paragraph sums up recent RNS & underpinned by prevail -
As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike..
👍 superb last line for all invested & patients in the future -
Always get your doommongers loitering on forums on stocks with potential , likely buying stock when shovelling doom dung on the forum , in my experience,
Imo - The stock price will re rate & the Grog will flow in investors tankards
Hemo on Ortex - very positive
& when you include Vlads recent interview- transformational yr for Hemo & investors
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform
(via NewsDirect)
Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.
Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolises a pivotal milestone, offering potential life-changing treatments for patients with limited options.
Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.
As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike..
👍 superb last line for all invested & patients in the future -
Always get your doommongers on stocks loitering on forums , likely buying when dooming in my experience.
Imo - The stock price will re rate & the Grog will flow in investors tankards
Morning majority
Looking forward to coming months , irrespective of recent market shenanigans, just re read the last 3 RNS & listen to Vlads latest interview all positive & of course Prevail stood underpinning potential science deals .
As noted on Ortex yesterday a very positive quote ;
As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike..
Grog will eventually flow for all invested .
Afternoon all - Hemo on Ortex - positive read for sure .
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform
(via NewsDirect)
Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.
Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolises a pivotal milestone, offering potential life-changing treatments for patients with limited options.
Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.
As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike..
👍 superb last line for all invested & patients in the future -
Imo - The stock price will re rate & the Grog will flow in investors tankards
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
Accesswire 18th
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial Cells
LONDON, UK / ACCESSWIRE / February 16, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered into the brain via programmed microglial cells for the potential treatment of brain cancers and certain neurodegenerative diseases.
Delivery of therapeutics across the blood-brain barrier is one of the most difficult problems in the treatment of brain cancers and certain neurodegenerative diseases. Our scientists at have developed a method of transplantation of human hematopoietic (blood) stem cells ("HSC") that allows their engraftment and differentiation into microglial cells (immune cells that reside in the brain) in the brains of immune-compromised mice.
The Company believes that autologous HSCs that are genetically modified to make CBR and transplanted back to a patient could give rise to microglial cells in the patient's brain. Such microglial cells that have been armed with CBR could potentially be able to find and phagocytose (ingest and destroy) either brain cancer cells or abnormal protein aggregations (e.g., amyloid plaques in Alzheimer's).
The Company's approach described above may offer a number of benefits: (1) it could deliver CBR therapeutics across the blood brain barrier; (2) CBR-armed microglial cells may not be rejected as they are autologous/patient-derived; (3) CBR-armed microglial cells may provide long-term protection of the brain against cancer or protein aggregations because microglial cells live for a long time; and (4) autologous HSC, which are self-renewing, could become an almost unlimited source of CBR-armed microglial cells for the patient.
This is a further indication of the growing range and versatility of CBR as a potential tool against a variety of difficult to treat and deadly conditions.
Research continues on CBR and the Company intends to increase its focus on this once HEMO-CAR-T has entered clinical trials.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR into the brain is a unique tool that may allow us to successfully tackle some of the most difficult and often incurable human diseases. As we broaden the scope of use for our CBR platform, we are eager to continue its development."
Evening all
Looking forward to coming weeks , irrespective of recent market shenanigans, just re read the last 3 RNS & listen to Vlads latest interview all positive & of course Prevail stood underpinning potential science deals .
Delayed reaction on stock news , perhaps or further news .
Orph & all
Morning ,
Certainly some market shenanigans of late , 3 cracking RNS yet in the 3s
Always sceptical on the markets , & was indeed a seller loitering in the shadows & the Ai bots in charge of trading .
Shorts only rose minimum & small %
The 6 month graph still looks very positive irrespective of recent reversal , heading in a north trajectory since Prevail got involved .
With these recent positive RNS & more in the pipeline on partnerships/ funding etc + Vlads interview , next few weeks / months could certainly be interesting for investors .
Any whiff of a large pharma involved / offer etc & stock price will be in double digits imo
Just patience required .
Fetch the Full English to soak up the Grog
Been on the grog ,
It’s been a superb week for RNS for Hemo investors & even better to come with Prevail pushing the financial buttons !
Unfortunately, not a great week for a mate of mine Randy Rick who got his sleeping tablets & Viagra mixed up & ended up having forty w.a.n.ks Ha ha 🤣
Just some grog fuelled humour after a great week on news ,
Morning all invested
Been a great week for RNS for Hemo & all invested
& some great info/ opinion posted from many on this forum .
Recent RNS
. CBR - Brain delivery
.CBR - intranasal delivery
.CAR T - clinical confirmed & underpinned via Prevail
Interview with Vlad also very positive & certainly cranking up what Hemo has to offer .
Hopefully a pharma deal of some sort , partnership, investment, or full buy out , on CAR T or CBR in the pipeline .
The markets will eventually re rate the stock for all invested .
Have a great weekend all & looking forward to coming months .
Closing Price 3.22 UT
Vol 19.7 million
Vwap 3.32
Auto vol 13 million
A superb week for RNS ,
3 x crackers in last 2 weeks , & Hemo multi pronged science unfolding
Stock price will follow eventually…
Have a great weekend all invested
A big bag of kippers - buys some delayed just been tossed on deck by the robots
16-Feb-24 15:48:05 3.267 300,000 Buy* 3.21 3.27 9,801 O
16-Feb-24 15:48:05 3.267 300,000 Buy* 3.21 3.27 9,801 O
16-Feb-24 14:32:15 3.271 455,974 Unknown* 3.21 3.27 14.91k O
16-Feb-24 15:25:52 3.26 113,621 Buy* 3.20 3.26 3,704 A
16-Feb-24 15:25:43 3.2646 332,071 Buy* 3.20 3.26 10.84k O
MrI & all
Tend to agree on the algo front ,as I’ve said before all seems very organised & orchestrated / controlled almost robotic
Algorythmic trading etc
Auto vol has been high 1m + for last few sessions .
Anyhow been a good week on the RNS front , stock price will follow once robots have had there party .
Bline & all
Agree with that dude ,
Hemos multi pronged science finally baring fruit
With that & the interview JFTH posted looks like a transformational yr for Hemo & investors imo
Fetch the Friday Grog
Monkey & all
So let me get this straight,
Your not & haven’t even been invested in Eua or Hemo yet telling others not to post there style because you don’t like it as your a Good Samaritan
You reek of agenda pal
I don’t post to encourage anyone to sell or buy , just post my position with humour .